Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC).
D. Cella
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
B. Escudier
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - AVEO; Bayer; Bayer; GlaxoSmithKline; Pfizer; Roche
B. I. Rini
Consultant or Advisory Role - AVEO; GlaxoSmithKline; Pfizer
Research Funding - GlaxoSmithKline; Pfizer
C. Chen
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
H. Bhattacharyya
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
J. C. Tarazi
Employment or Leadership Position - Pfizer
B. Rosbrook
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
S. Kim
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
R. J. Motzer
Research Funding - Pfizer